MingMed Biotech key facts
as of Oct 2026- Developer of pharmaceutical drugs intended for global pharmaceutical markets and healthcare providers.
- MingMed Biotech is valued at approximately $615.4M as of Oct 2026 (last reported valuation).
- It has raised $139.8M; the latest was Later Stage VC ($3.5M) in Apr 2025.
- Notable investors include CAS Star, Shenzhen Yifeng Investment Management Enterprise, Oceanpine Capital, Hengqin Financial Investment, Taiping Life Insurance Company — 16 tracked in total.
- Status: Privately Held (backing).
MingMed Biotech's last reported valuation, Jul 2022. Nothing priced has surfaced since.
- ·The complete investor list: 16 names
- ·Watch MingMed Biotech: the Monday email on marks, rounds and moves
MingMed Biotech funding rounds
No funding rounds for MingMed Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs MingMed Biotech
16+MingMed Biotech valuation
MingMed Biotech's last reported valuation was $615 million in Jul 2022. No priced round, secondary trade or fund mark has surfaced since.
MingMed Biotech investors
16 investors are on record for MingMed Biotech, including CAS Star, Shenzhen Yifeng Investment Management Enterprise, Oceanpine Capital and Hengqin Financial Investment.
About MingMed Biotech
Developer of pharmaceutical drugs intended for global pharmaceutical markets and healthcare providers. The company develops ophthalmic drugs, small-molecule immune drugs, and cell therapies based on gene editing, thereby providing innovative products to ophthalmology, medical beauty, and pet medicine.
- Sector
- Healthcare
- HQ
- Guangzhou, China
- Founded
- 2019
- Employees
- 230
- Website
- ming-med.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.